Pharma major Dr Reddy’s Laboratories Ltd has launched Ramelteon tablets, a therapeutically equivalent generic version of Rozerem (ramelteon) tablets, approved by the US Food and Drug Administration (USFDA).
The Rozerem brand had US sales of approximately $91.3 million for the most recent twelve months ending in May 2019 according to IQVIA Health. Rozerem is a trademark of Takeda Pharmaceutical Company Limited, the Hyderabad-based company said in a release.
Dr Reddy’s Ramelteon Tablets, are available as 8 mg tablets in bottle count sizes of 30, 100, and 1000.